Cancers
14 results
Applied filters
Thiotepa: informing intrathecal risk assessment
29 October 2025Thiotepa products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Etoposide: informing intrathecal risk assessment
29 October 2025Etoposide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Rituximab: informing intrathecal risk assessment
29 October 2025Rituximab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Cytarabine: informing intrathecal risk assessment
5 August 2025Cytarabine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Understanding risks with intrathecal administration
17 June 2025The intrathecal route is a high-risk route of administration. Incorrect administration of medicines unsafe for this route can result in patient death.
Preventing harm from incorrect vinca alkaloid administration
13 June 2025Vinca alkaloids can cause paralysis and death if given by the wrong route. Understand how to reduce the risk to patients.
Managing an intrathecal chemotherapy service
13 June 2025The intrathecal route is a high-risk route of administration. There are minimum requirements for providing intrathecal chemotherapy.
Switching between morphine and other opioids in palliative care
1 April 2025Switching between oral morphine and other oral opioids requires care and thoughtful application of a stepped process.
Estimating dose equivalence from oral morphine to other opioids
1 April 2025Use our tool to obtain approximate dose equivalences of oral morphine to other oral opioids and help you calculate an estimated equivalent daily dose.
Trastuzumab: informing intrathecal risk assessment
19 February 2024Trastuzumab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration